200 related articles for article (PubMed ID: 29909645)
1. Minimizing Patient Burden Through the Use of Historical Subject-Level Data in Innovative Confirmatory Clinical Trials: Review of Methods and Opportunities.
Lim J; Walley R; Yuan J; Liu J; Dabral A; Best N; Grieve A; Hampson L; Wolfram J; Woodward P; Yong F; Zhang X; Bowen E
Ther Innov Regul Sci; 2018 Sep; 52(5):546-559. PubMed ID: 29909645
[TBL] [Abstract][Full Text] [Related]
2. Dynamic use of historical controls in clinical trials for rare disease research: A re-evaluation of the MILES trial.
Harun N; Gupta N; McCormack FX; Macaluso M
Clin Trials; 2023 Jun; 20(3):223-234. PubMed ID: 36927115
[TBL] [Abstract][Full Text] [Related]
3. Incorporating individual historical controls and aggregate treatment effect estimates into a Bayesian survival trial: a simulation study.
Brard C; Hampson LV; Gaspar N; Le Deley MC; Le Teuff G
BMC Med Res Methodol; 2019 Apr; 19(1):85. PubMed ID: 31018832
[TBL] [Abstract][Full Text] [Related]
4. Using Bayesian statistics in confirmatory clinical trials in the regulatory setting: a tutorial review.
Lee SY
BMC Med Res Methodol; 2024 May; 24(1):110. PubMed ID: 38714936
[TBL] [Abstract][Full Text] [Related]
5. Design of randomized controlled confirmatory trials using historical control data to augment sample size for concurrent controls.
Yuan J; Liu J; Zhu R; Lu Y; Palm U
J Biopharm Stat; 2019; 29(3):558-573. PubMed ID: 30612514
[TBL] [Abstract][Full Text] [Related]
6. Leveraging historical data into oncology development programs: Two case studies of phase 2 Bayesian augmented control trial designs.
Smith CL; Thomas Z; Enas N; Thorn K; Lahn M; Benhadji K; Cleverly A
Pharm Stat; 2020 May; 19(3):276-290. PubMed ID: 31903699
[TBL] [Abstract][Full Text] [Related]
7. Robust meta-analytic-predictive priors in clinical trials with historical control information.
Schmidli H; Gsteiger S; Roychoudhury S; O'Hagan A; Spiegelhalter D; Neuenschwander B
Biometrics; 2014 Dec; 70(4):1023-32. PubMed ID: 25355546
[TBL] [Abstract][Full Text] [Related]
8. Propensity score-integrated Bayesian prior approaches for augmented control designs: a simulation study.
Wang X; Suttner L; Jemielita T; Li X
J Biopharm Stat; 2022 Jan; 32(1):170-190. PubMed ID: 34939894
[TBL] [Abstract][Full Text] [Related]
9. Design and analysis of a clinical trial using previous trials as historical control.
Schoenfeld DA; Finkelstein DM; Macklin E; Zach N; Ennist DL; Taylor AA; Atassi N;
Clin Trials; 2019 Oct; 16(5):531-538. PubMed ID: 31256630
[TBL] [Abstract][Full Text] [Related]
10. Power priors based on multiple historical studies for binary outcomes.
Gravestock I; Held L
Biom J; 2019 Sep; 61(5):1201-1218. PubMed ID: 30325059
[TBL] [Abstract][Full Text] [Related]
11. A practical Bayesian adaptive design incorporating data from historical controls.
Psioda MA; Soukup M; Ibrahim JG
Stat Med; 2018 Nov; 37(27):4054-4070. PubMed ID: 30033617
[TBL] [Abstract][Full Text] [Related]
12. Using historical control information for the design and analysis of clinical trials with overdispersed count data.
Gsteiger S; Neuenschwander B; Mercier F; Schmidli H
Stat Med; 2013 Sep; 32(21):3609-22. PubMed ID: 23722585
[TBL] [Abstract][Full Text] [Related]
13. Incorporating historical information in biosimilar trials: Challenges and a hybrid Bayesian-frequentist approach.
Mielke J; Schmidli H; Jones B
Biom J; 2018 May; 60(3):564-582. PubMed ID: 29532950
[TBL] [Abstract][Full Text] [Related]
14. Bayesian sample size for exploratory clinical trials incorporating historical data.
Whitehead J; Valdés-Márquez E; Johnson P; Graham G
Stat Med; 2008 Jun; 27(13):2307-27. PubMed ID: 18069728
[TBL] [Abstract][Full Text] [Related]
15. Bayesian adaptive randomization design incorporating propensity score-matched historical controls.
Sawamoto R; Oba K; Matsuyama Y
Pharm Stat; 2022 Sep; 21(5):1074-1089. PubMed ID: 35278032
[TBL] [Abstract][Full Text] [Related]
16. Utilizing shared internal control arms and historical information in small-sized platform clinical trials.
Jiao F; Tu W; Jimenez S; Crentsil V; Chen YF
J Biopharm Stat; 2019; 29(5):845-859. PubMed ID: 31462131
[TBL] [Abstract][Full Text] [Related]
17. Historical controls in clinical trials: a note on linking Pocock's model with the robust mixture priors.
Callegaro A; Galwey N; Abellan JJ
Biostatistics; 2023 Apr; 24(2):443-448. PubMed ID: 37057610
[TBL] [Abstract][Full Text] [Related]
18. Addressing prior-data conflict with empirical meta-analytic-predictive priors in clinical studies with historical information.
Li JX; Chen WC; Scott JA
J Biopharm Stat; 2016; 26(6):1056-1066. PubMed ID: 27541990
[TBL] [Abstract][Full Text] [Related]
19. The inclusion of historical control data may reduce the power of a confirmatory study.
Cuffe RL
Stat Med; 2011 May; 30(12):1329-38. PubMed ID: 21432893
[TBL] [Abstract][Full Text] [Related]
20. Use of a historical control group in a noninferiority trial assessing a new antibacterial treatment: A case study and discussion of practical implementation aspects.
Dejardin D; Delmar P; Warne C; Patel K; van Rosmalen J; Lesaffre E
Pharm Stat; 2018 Mar; 17(2):169-181. PubMed ID: 29282862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
